Jon Congleton
Jon is an Operating Partner with Catalys Pacific and CEO of Mineralys Therapeutics Inc., a Catalys Pacific portfolio company. Jon brings 35 years of pharmaceutical experience including roles as CEO of both private and public companies. He has worked in cardiovascular, GI and CNS companies with a focus on providing solutions for patients and their caregivers. He has launched several life changing therapies such as Copaxone and Azilect.
Prior to his current position, he was CEO of Impel NeuroPharma, a private biotech company focused on CNS disorders through novel upper nasal cavity delivery. Previously, he served as CEO at Nivalis Therapeutics which he took public in 2015 and was focused on treatments for cystic fibrosis. Jon held multiple roles of ascending responsibility at Teva Pharmaceuticals. He was part of the original team responsible for the launch of Copaxone for multiple sclerosis in the United States ultimately leading the U.S. neuroscience business and global CNS franchise.
Mr. Congleton attend Kansas State University, where he graduated with a B.S. in marketing and a minor in microbiology.
“Far and away the best prize that life offers is the chance to work hard at work worth doing.”
